|By PR Newswire||
|January 20, 2014 09:16 AM EST||
NEW YORK, Jan. 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Protein based therapies have found a prominent place in the biopharmaceutical industry since the launch of the human insulin product. They have become one of the most effective clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic disorders. The market holds tremendous potential for future growth and it is estimated that by the end of 2018, it may reach the mark of US$ 165 Billion as new products (especially monoclonal antibodies in the advanced clinical phase) may enter the sector.
According to our new research report, "Global Protein Therapeutics Market Outlook 2018", a large number of market players has been developing monoclonal antibodies (mAbs). Our research has found that mAbs contribute the largest shares in the number of protein therapeutic products under pipeline. The report, in this context, gives a comprehensive analysis of the current and future patterns of revenue generation with respect to mAbs and other segments.
Through in-depth and prudent analysis of the developments taking place at the global level, we have observed that the US holds a dominant position in the global protein therapeutics market as the country provides a major proportion of the products' sales. However, our team of researchers has come up with an analysis that the future landscape of the market may find positive developments from Asian countries as huge patients' population and increasing disposable incomes may turn out to be a win-win condition for industry participants.
The report also covers an advanced phase drug analysis. This chapter lists all the protein therapeutics of the major players which are in the third phase of the clinical trial. This analysis will help the client in understanding the potential market for the future. It also helps understand the major segments, indications and players in Protein Therapeutics that will continue to rule the market.
The report takes into account all the key aspects of the worldwide protein therapeutics market and projects the market during the period 2012-2018. It prudently analyzes all the industry segments in an effective manner by focusing on major players and products, recent developments, application support in terms of indications, geographical performances and last but not the least, current and future market sizes. Moreover, the report provides a summary of the recent trends that may have an impact on the future industry performance.
At the end, the key players of the market have been enlisted. A brief business overview of every player has been provided alongwith its product portfolio. This is followed by the recent developments of the player that may impact the market in the future. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Global Protein Therapeutics Market
3.1 Protein Therapeutics Market vs Pharmaceutical Market
3.2 Current and Future Market Analysis to 2018
3.2.1 Market Segmentation
4. Industry Performance
4.1 Monoclonal Antibodies (mAbs)
4.1.1 Scientific Insight
4.1.2 Current and Future Market Analysis to 2018
4.1.3 By Application
4.1.4 Key Geographical Markets
4.1.5 Key Players and Drugs
4.1.6 Recent Developments
4.2 Erythropoietin (EPO)
4.2.1 Scientific Insight
4.2.2 Current and Future Market Analysis to 2018
4.2.3 By Application
4.2.4 Key Geographical Markets
4.2.5 Key Players and Drugs
4.2.6 Recent Developments
4.3.1 Scientific Insight
4.3.2 Current and Future Market Analysis to 2018
4.3.3 By Application
4.3.4 Key Geographical Markets
4.3.5 Key Players and Drugs
4.3.6 Recent Developments
4.4 Interferon (IFN)
4.4.1 Scientific Insight
4.4.2 Current and Future Market Analysis to 2018
4.4.3 By Application
4.4.4 Key Geographical Markets
4.4.5 Key Players and Drugs
4.4.6 Recent Developments
4.5 Human Growth Hormone (HGH)
4.5.1 Scientific Insight
4.5.2 Current and Future Market Analysis to 2018
4.5.3 Key Geographical Markets
4.5.4 Key Players and Drugs
4.5.5 Recent Developments
4.6 Blood Clotting Factor
4.6.1 Scientific Insight
4.6.2 Current and Future Market Analysis to 2018
4.6.3 Key Players and Drugs
4.6.4 Recent Developments
4.7 Follicle Stimulating Hormone (FSH)
4.7.1 Scientific Insight
4.7.2 Current and Future Market Analysis to 2018
4.7.3 Key Players and Drugs
4.7.4 Recent Developments
4.8 Granulocyte Colony Stimulating Factor (G-CSF)
4.8.1 Scientific Insight
4.8.2 Current and Future Market Analysis to 2018
4.8.3 Key Players and Drugs
4.8.4 Recent Developments
5. Advanced Phase Drugs Analysis
6. Emerging Market Trends
6.1 Gaining Momentum: Strategic Activities among Players to Develop Novel Treatments
6.2 Effective Delivery Methods: Improving the Reach of Therapies
6.3 Players Investing Heavily in Multiple Sclerosis and Cancer Therapeutics
7. Key Players
7.1 Johnson & Johnson
7.2 Biogen Idec Inc.
7.3 Eli Lilly & Company
7.5 Merck Serono S.A.
7.6 Roche Group
7.7 Amgen Inc.
7.9 Abbott Laboratories
7.10 Novo Nordisk
List of Figures:
Figure 3-1: Global - Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2012
Figure 3-2: Global - Protein Therapeutics Market (Billion US$), 2012-2018
Figure 3-3: Global - Protein Therapeutics Market by Segment (%), 2012
Figure 3-4: Global - Forecast for Protein Therapeutics Market by Segment (%), 2018
Figure 4-1: Global - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-2: Global - Monoclonal Antibodies Market by Application (%), 2012
Figure 4-3: Global - Use of Monoclonal Antibodies in Cancer Treatment (Billion US$), 2011 & 2012
Figure 4-4: Global - Use of Monoclonal Antibodies in Rheumatoid Arthritis Treatment (Billion US$), 2011 & 2012
Figure 4-5: Global - Use of Monoclonal Antibodies in Other Chronic Diseases Treatment (Billion US$), 2011 & 2012
Figure 4-6: US - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-7: Europe - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-8: Japan - Monoclonal Antibodies Market (Billion US$), 2012-2018
Figure 4-9: Global - Erythropoietin Market (Billion US$), 2012-2018
Figure 4-10: Global - Number of Patients on Dialysis (Million), 2010-2012
Figure 4-11: Global - Breakup of Patients on Dialysis by Region (%), 2012
Figure 4-12: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 4-13: Global - Breakup of New Cancer Cases by Region (%), 2009
Figure 4-14: Global - Share of US in EPO Market (2012)
Figure 4-15: Global - Insulin Market (Billion US$), 2012-2018
Figure 4-16: Global - Number of Diabetic Patients (Million), 2012 & 2030
Figure 4-17: China - Insulin Market (Billion US$), 2012-2018
Figure 4-18: US - Insulin Market (Billion US$), 2012-2018
Figure 4-19: Japan - Insulin Market (Billion US$), 2012-2018
Figure 4-20: Global - Share of Key Players in Insulin Market (2012)
Figure 4-21: Global - Share of Products in Insulin Market (2012)
Figure 4-22: Global - Interferon Market (Billion US$), 2012-2018
Figure 4-23: Global - Share of Alpha and Beta Products in Interferon Market (2012)
Figure 4-24: Global - Interferon Alpha Market (Billion US$), 2010-2012
Figure 4-25: Global - Interferon Beta Market (Billion US$), 2010-2012
Figure 4-26: US - Interferon Market (Billion US$), 2010-2012
Figure 4-27: Japan - Interferon Market (Million US$), 2010-2012
Figure 4-28: Global - Human Growth Hormone Market (Billion US$), 2012-2018
Figure 4-29: Global - Share of Key Players in Human Growth Hormone Market (2012)
Figure 4-30: Global - Blood Clotting Factor Market (Billion US$), 2012-2018
Figure 4-31: Global - Share of Blood Clotting Factor Market by Segment (2012)
Figure 4-32: Global - Share of Key Players in Blood Clotting Factor Market (2012)
Figure 4-33: Global - Follicle Stimulating Hormone Market (Billion US$), 2012-2018
Figure 4-34: Global - Granulocyte Colony Stimulating Factor Market (Billion US$), 2012-2018
List of Tables:
Table 4-1: Global - Key Players and Drugs in Monoclonal Antibody Market (Billion US$), 2010-2012
Table 4-2: US - Sales of Key EPO Products (Billion US$), 2010-2012
Table 4-3: Global - Key Players and Drugs in Erythropoietin Alfa Market (Billion US$), 2010-2012
Table 4-4: Global - Key Players and Drugs in Erythropoietin Beta Market (Billion US$), 2010-2012
Table 4-5: Global - Key Players and Drugs in Darbepoetin Market (Billion US$), 2010-2012
Table 4-6: China - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-7: US - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030f
Table 4-8: Japan - Diabetic Patients in Age Group 20-79 Years ('000), 2012 & 2030
Table 4-9: Global - Key Players and Drugs in Interferon Alpha Market (Billion US$), 2010-2012
Table 4-10: Global - Key Players and Drugs in Interferon Beta Market (Billion US$), 2010-2012
Table 4-11: Global - Key Players and Drugs in Human Growth Hormone Market (Billion US$), 2010-2012
Table 4-12: Global - Key Players and Drugs in Blood Clotting Factor Market (Billion US$), 2010-2012
Table 4-13: Global - Key Players and Drugs in Follicle Stimulating Hormone Market (Billion US$), 2010-2012
Table 4-14: Global - Key Players and Drugs in Granulocyte Colony Stimulating Factor Market (Billion US$), 2010-2012
Table 5-1: Advanced Phase Protein Therapeutics
Table 7-1: Johnson & Johnson - Key Products in Protein Therapeutics
Table 7-2: Biogen Idec - Key Products in Protein Therapeutics
Table 7-3: Eli Lilly - Key Products in Protein Therapeutics
Table 7-4: Sanofi-Aventis - Key Products in Protein Therapeutics
Table 7-5: Merck Serono - Key Products in Protein Therapeutics
Table 7-6: Roche - Key Products in Protein Therapeutics
Table 7-7: Amgen Inc. - Key Products in Protein Therapeutics
Table 7-8: Pfizer Inc. - Key Products in Protein Therapeutics
Table 7-9: Abbott Laboratories - Key Products in Protein Therapeutics
Table 7-10: Novo Nordisk - Key Products in Protein Therapeutics
To order this report: Global Protein Therapeutics Market Outlook 2018
Contact Clare: [email protected]
Intl: +1 339-368-6001
A completely new computing platform is on the horizon. They’re called Microservers by some, ARM Servers by others, and sometimes even ARM-based Servers. No matter what you call them, Microservers will have a huge impact on the data center and on server computing in general. Although few people are familiar with Microservers today, their impact will be felt very soon. This is a new category of computing platform that is available today and is predicted to have triple-digit growth rates for some ...
Oct. 21, 2016 10:00 PM EDT Reads: 33,886
You think you know what’s in your data. But do you? Most organizations are now aware of the business intelligence represented by their data. Data science stands to take this to a level you never thought of – literally. The techniques of data science, when used with the capabilities of Big Data technologies, can make connections you had not yet imagined, helping you discover new insights and ask new questions of your data. In his session at @ThingsExpo, Sarbjit Sarkaria, data science team lead ...
Oct. 21, 2016 10:00 PM EDT Reads: 4,197
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 21, 2016 09:30 PM EDT Reads: 614
Effectively SMBs and government programs must address compounded regulatory compliance requirements. The most recent are Controlled Unclassified Information and the EU’s GDPR have Board Level implications. Managing sensitive data protection will likely result in acquisition criteria, demonstration requests and new requirements. Developers, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by incorporating changes.
Oct. 21, 2016 09:30 PM EDT Reads: 1,578
SYS-CON Events announced today that Roundee / LinearHub will exhibit at the WebRTC Summit at @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LinearHub provides Roundee Service, a smart platform for enterprise video conferencing with enhanced features such as automatic recording and transcription service. Slack users can integrate Roundee to their team via Slack’s App Directory, and '/roundee' command lets your video conference ...
Oct. 21, 2016 09:15 PM EDT Reads: 1,975
SYS-CON Events announced today that Enzu will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive advantage. By offering a suite of proven hosting and management services, Enzu wants companies to focus on the core of their online busine...
Oct. 21, 2016 09:15 PM EDT Reads: 1,189
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and...
Oct. 21, 2016 08:15 PM EDT Reads: 323
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Oct. 21, 2016 07:15 PM EDT Reads: 1,608
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining senso...
Oct. 21, 2016 07:15 PM EDT Reads: 241
@ThingsExpo has been named the Top 5 Most Influential Internet of Things Brand by Onalytica in the ‘The Internet of Things Landscape 2015: Top 100 Individuals and Brands.' Onalytica analyzed Twitter conversations around the #IoT debate to uncover the most influential brands and individuals driving the conversation. Onalytica captured data from 56,224 users. The PageRank based methodology they use to extract influencers on a particular topic (tweets mentioning #InternetofThings or #IoT in this ...
Oct. 21, 2016 07:00 PM EDT Reads: 8,103
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Oct. 21, 2016 07:00 PM EDT Reads: 8,924
The IoT has the potential to create a renaissance of manufacturing in the US and elsewhere. In his session at 18th Cloud Expo, Florent Solt, CTO and chief architect of Netvibes, discussed how the expected exponential increase in the amount of data that will be processed, transported, stored, and accessed means there will be a huge demand for smart technologies to deliver it. Florent Solt is the CTO and chief architect of Netvibes. Prior to joining Netvibes in 2007, he co-founded Rift Technologi...
Oct. 21, 2016 06:45 PM EDT Reads: 2,813
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Oct. 21, 2016 06:45 PM EDT Reads: 1,857
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
Oct. 21, 2016 06:15 PM EDT Reads: 3,014
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Oct. 21, 2016 05:15 PM EDT Reads: 2,814